Cargando…
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
PURPOSE: This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients with BCR PC after primary definitive therapy and p...
Autores principales: | Aggarwal, Rahul, Alumkal, Joshi J., Szmulewitz, Russell Z., Higano, Celestia S., Bryce, Alan H., Lopez-Gitlitz, Angela, McCarthy, Sharon A., Miladinovic, Branko, McQuarrie, Kelly, Thomas, Shibu, Zhang, Ke, Small, Eric J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534720/ https://www.ncbi.nlm.nih.gov/pubmed/36212187 http://dx.doi.org/10.1155/2022/5454727 |
Ejemplares similares
-
Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023) -
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
por: Smith, Matthew R., et al.
Publicado: (2016) -
Hypothyroidism caused by apalutamide
por: Daviduck, Quinn, et al.
Publicado: (2023) -
Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients
por: Liu, Jinan, et al.
Publicado: (2013) -
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)